Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Roflumilast (Daxas®) has been rejected as an add on to bronchodilator treatment in severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in 1 second post-bronchodilator <50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. The manufacturer did not present a sufficiently robust economic analysis.

Four combined oral contraceptive pills (Rigevidon®, Gedarel®, Millinette® and TriRegol®) were all accepted for use in patients where these products would provide an appropriate form of contraception. They provide an alternative to the existing preparations at a lower cost.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2010' on Email Share 'SMC Update - October 2010' on Delicious Share 'SMC Update - October 2010' on Digg Share 'SMC Update - October 2010' on Facebook Share 'SMC Update - October 2010' on reddit Share 'SMC Update - October 2010' on StumbleUpon Share 'SMC Update - October 2010' on Twitter

atomic-wealth

No Comments to “SMC Update - October 2010”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer